Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Lusk CM, Watza D, Dyson G, Craig D, Ratliff V, Wenzlaff AS, Lonardo F, Bollig-Fischer A, Bepler G, Purrington K, Gadgeel S, Schwartz AG.

Clin Cancer Res. 2019 Jul 15;25(14):4300-4308. doi: 10.1158/1078-0432.CCR-18-2439. Epub 2019 Apr 12.

PMID:
30979741
2.

HDAC6 regulates DNA damage response via deacetylating MLH1.

Zhang M, Hu C, Moses N, Haakenson J, Xiang S, Quan D, Fang B, Yang Z, Bai W, Bepler G, Li GM, Zhang XM.

J Biol Chem. 2019 Apr 12;294(15):5813-5826. doi: 10.1074/jbc.RA118.006374. Epub 2019 Feb 15.

PMID:
30770470
3.

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.

4.

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.

Heyza JR, Lei W, Watza D, Zhang H, Chen W, Back JB, Schwartz AG, Bepler G, Patrick SM.

Clin Cancer Res. 2019 Apr 15;25(8):2523-2536. doi: 10.1158/1078-0432.CCR-18-3094. Epub 2018 Dec 11.

PMID:
30538112
5.

Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor.

Patki M, McFall T, Rosati R, Huang Y, Malysa A, Polin L, Fielder A, Wilson MR, Lonardo F, Back J, Li J, Matherly LH, Bepler G, Ratnam M.

Sci Rep. 2018 Oct 30;8(1):16006. doi: 10.1038/s41598-018-34475-8.

6.

Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes.

Watza D, Lusk CM, Dyson G, Purrington KS, Chen K, Wenzlaff AS, Ratliff V, Neslund-Dudas C, Bepler G, Schwartz AG.

Carcinogenesis. 2018 Dec 31;39(12):1447-1454. doi: 10.1093/carcin/bgy119.

PMID:
30202894
7.

A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.

Cheriyan VT, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, Bepler G, Iyer AK, Singh M, Rishi AK.

Oncotarget. 2018 Jul 3;9(51):29680-29697. doi: 10.18632/oncotarget.25671. eCollection 2018 Jul 3.

8.

RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Chammaa M, Malysa A, Redondo C, Jang H, Chen W, Bepler G, Fernandez-Valdivia R.

J Cell Physiol. 2018 Dec;233(12):9548-9562. doi: 10.1002/jcp.26858. Epub 2018 Jun 28.

PMID:
29953591
9.

Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.

Wu JY, Xiang S, Zhang M, Fang B, Huang H, Kwon OK, Zhao Y, Yang Z, Bai W, Bepler G, Zhang XM.

J Biol Chem. 2018 Feb 9;293(6):1976-1993. doi: 10.1074/jbc.M117.795955. Epub 2017 Dec 19.

10.

A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.

Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22856. No abstract available.

11.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.

Farrell JJ, Moughan J, Wong JL, Regine WF, Schaefer P, Benson AB 3rd, Macdonald JS, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H.

Pancreas. 2016 Nov;45(10):1485-1493.

12.

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.

Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072.

13.

Standardizing Assessment of Competences and Competencies of Oncology Nurses Working in Ambulatory Care.

Beaver C, Magnan MA, Henderson D, DeRose P, Carolin K, Bepler G.

J Nurses Prof Dev. 2016 Mar-Apr;32(2):64-73; quiz E6. doi: 10.1097/NND.0000000000000250.

PMID:
26985750
14.

Ubiquitin-specific Peptidase 10 (USP10) Deubiquitinates and Stabilizes MutS Homolog 2 (MSH2) to Regulate Cellular Sensitivity to DNA Damage.

Zhang M, Hu C, Tong D, Xiang S, Williams K, Bai W, Li GM, Bepler G, Zhang X.

J Biol Chem. 2016 May 13;291(20):10783-91. doi: 10.1074/jbc.M115.700047. Epub 2016 Mar 14.

15.

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.

Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A.

Clin Cancer Res. 2016 May 15;22(10):2396-404. doi: 10.1158/1078-0432.CCR-15-1468. Epub 2015 Dec 15.

16.

RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis.

Zheng SD, Bui K, Chiappori A, Bepler G, Bui MM.

Pathol Oncol Res. 2016 Jul;22(3):477-82. doi: 10.1007/s12253-015-0021-x. Epub 2015 Nov 26.

PMID:
26612755
17.

Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry.

Wu J, Zhang Y, Wiegand R, Wang J, Bepler G, Li J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 1;1006:167-178. doi: 10.1016/j.jchromb.2015.10.030. Epub 2015 Oct 31.

18.

Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.

Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ.

Cancer Immunol Res. 2015 Jul;3(7):777-86. doi: 10.1158/2326-6066.CIR-14-0175. Epub 2015 Feb 23.

19.

β-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition.

Pillai S, Trevino J, Rawal B, Singh S, Kovacs M, Li X, Schell M, Haura E, Bepler G, Chellappan S.

Cancer Res. 2015 Mar 15;75(6):1009-20. doi: 10.1158/0008-5472.CAN-14-0681. Epub 2015 Jan 19.

20.

Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.

Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.

J Thorac Oncol. 2014 Nov;9(11):1704-8. doi: 10.1097/JTO.0000000000000285.

21.

A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.

Wijesinghe P, Bepler G, Bollig-Fischer A.

J Thorac Oncol. 2015 Feb;10(2):381-6. doi: 10.1097/JTO.0000000000000337.

22.

Racial diversity of actionable mutations in non-small cell lung cancer.

Bollig-Fischer A, Chen W, Gadgeel SM, Wenzlaff AS, Cote ML, Schwartz AG, Bepler G.

J Thorac Oncol. 2015 Feb;10(2):250-5. doi: 10.1097/JTO.0000000000000420.

23.

HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.

Zhang M, Xiang S, Joo HY, Wang L, Williams KA, Liu W, Hu C, Tong D, Haakenson J, Wang C, Zhang S, Pavlovicz RE, Jones A, Schmidt KH, Tang J, Dong H, Shan B, Fang B, Radhakrishnan R, Glazer PM, Matthias P, Koomen J, Seto E, Bepler G, Nicosia SV, Chen J, Li C, Gu L, Li GM, Bai W, Wang H, Zhang X.

Mol Cell. 2014 Jul 3;55(1):31-46. doi: 10.1016/j.molcel.2014.04.028. Epub 2014 May 29.

24.

A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).

Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR.

Cancer. 2014 Aug 1;120(15):2343-51. doi: 10.1002/cncr.28714. Epub 2014 Apr 18.

25.

Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.

Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M.

J Thorac Oncol. 2014 Apr;9(4):519-26. doi: 10.1097/JTO.0000000000000111.

26.

Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas.

Vaezi AE, Bepler G, Bhagwat NR, Malysa A, Rubatt JM, Chen W, Hood BL, Conrads TP, Wang L, Kemp CE, Niedernhofer LJ.

Cancer. 2014 Jun 15;120(12):1898-907. doi: 10.1002/cncr.28643. Epub 2014 Apr 1.

27.

Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabine.

Zhang Y, Li X, Chen Z, Bepler G.

PLoS One. 2014 Mar 10;9(3):e91186. doi: 10.1371/journal.pone.0091186. eCollection 2014.

28.

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, Kish JA, Kreahling J, Lush R, Neuger A, Tetteh L, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S.

Clin Cancer Res. 2014 Mar 15;20(6):1644-55. doi: 10.1158/1078-0432.CCR-13-2235. Epub 2014 Jan 15.

30.

Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients.

Gadgeel SM, Bepler G.

Future Oncol. 2013 Dec;9(12):1909-21. doi: 10.2217/fon.13.160.

PMID:
24295420
31.

Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.

Gadgeel SM, Chen W, Cote ML, Bollig-Fischer A, Land S, Schwartz AG, Bepler G.

PLoS One. 2013 Nov 8;8(11):e79820. doi: 10.1371/journal.pone.0079820. eCollection 2013.

32.

Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration.

Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, Wang C, Bai W, Zhang X.

J Biol Chem. 2013 Nov 15;288(46):33156-70. doi: 10.1074/jbc.M113.472506. Epub 2013 Oct 2.

33.

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A.

J Immunother. 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237.

34.
35.

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR.

J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20.

36.

A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.

Zhou J, Chen Z, Malysa A, Li X, Oliveira P, Zhang Y, Bepler G.

PLoS One. 2013;8(3):e58091. doi: 10.1371/journal.pone.0058091. Epub 2013 Mar 4.

37.

Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks.

Bastian LA, Fish LJ, Peterson BL, Biddle AK, Garst J, Lyna P, Molner S, Bepler G, Kelley M, Keefe FJ, McBride CM.

Am J Health Promot. 2013 Jan-Feb;27(3):181-90. doi: 10.4278/ajhp.101122-QUAN-387.

PMID:
23286595
38.

Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.

Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G.

Cancer. 2013 Mar 1;119(5):1023-32. doi: 10.1002/cncr.27836. Epub 2012 Oct 12.

39.

Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.

Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G, Zhang X.

PLoS One. 2012;7(9):e44265. doi: 10.1371/journal.pone.0044265. Epub 2012 Sep 5.

40.

On Bayesian methods of exploring qualitative interactions for targeted treatment.

Chen W, Ghosh D, Raghunathan TE, Norkin M, Sargent DJ, Bepler G.

Stat Med. 2012 Dec 10;31(28):3693-707. doi: 10.1002/sim.5429. Epub 2012 Jun 26.

41.

Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.

Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB.

J Oncol Pract. 2011 Nov;7(6):e25-31.

42.

Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One. 2012;7(2):e31331. doi: 10.1371/journal.pone.0031331. Epub 2012 Feb 15.

43.

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.

44.

Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay.

Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL.

Cancer. 2012 Mar 15;118(6):1607-18. doi: 10.1002/cncr.26450. Epub 2011 Aug 25.

45.

Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.

Chen Z, Zhou J, Zhang Y, Bepler G.

Biochem Biophys Res Commun. 2011 Sep 23;413(2):383-8. doi: 10.1016/j.bbrc.2011.08.111. Epub 2011 Aug 27.

46.

Crizotinib: an anaplastic lymphoma kinase inhibitor.

Gadgeel SM, Bepler G.

Future Oncol. 2011 Aug;7(8):947-53. doi: 10.2217/fon.11.77.

PMID:
21823889
47.

ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.

Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S.

Mol Cell Biol. 2011 Jul;31(14):3052-67. doi: 10.1128/MCB.01311-10. Epub 2011 May 23.

48.

Proactive recruitment of cancer patients' social networks into a smoking cessation trial.

Bastian LA, Fish LJ, Peterson BL, Biddle AK, Garst J, Lyna P, Molner S, Bepler G, Kelley M, Keefe FJ, McBride CM.

Contemp Clin Trials. 2011 Jul;32(4):498-504. doi: 10.1016/j.cct.2011.03.006. Epub 2011 Mar 5.

49.

Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.

Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier SP.

J Thorac Oncol. 2011 Mar;6(3):627-30. doi: 10.1097/JTO.0b013e31820a0ec0.

50.

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.

Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C.

J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88.

Supplemental Content

Loading ...
Support Center